Enanta Pharmaceuticals Inc. (ENTA) 近日宣布,其研发管线中的重要候选药物EDP-978正按计划推进。公司预计将在2026年第一季度向监管机构提交新药临床试验(IND)申请,并计划在同年第四季度公布该药物的第一阶段临床研究数据。这一进展标志着EDP-978的研发进程迈入了新的关键阶段。
Enanta Pharmaceuticals Inc. (ENTA) 近日宣布,其研发管线中的重要候选药物EDP-978正按计划推进。公司预计将在2026年第一季度向监管机构提交新药临床试验(IND)申请,并计划在同年第四季度公布该药物的第一阶段临床研究数据。这一进展标志着EDP-978的研发进程迈入了新的关键阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.